贝达药业：国家药监局批准帕妥珠单抗注射液上市

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its collaboration with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to market the biosimilar drug Pertuzumab injection (brand name: Bezetin®) for early and metastatic breast cancer patients [1] Group 1 - The drug Bezetin® is a biosimilar of Pertuzumab, independently developed by Bozhi Rui Biopharmaceutical [1] - The approval allows the company to advance the commercialization efforts for Bezetin® [1] - Bezetin® is indicated for the treatment of early breast cancer and metastatic breast cancer [1]